A turning point for microbiome medicines

Microbiome therapeutics are coming up on a pivotal moment, STAT’s Kate Sheridan writes. Three companies in this space plan to unveil late-stage trial results later this year — which will either validate the field, or cast doubt on whether drugging gut bugs and their ilk is even viable.

Seres Therapeutics, in particular, is being closely watched. Its oral C. diff treatment, SER-109, has Phase 3 results slated for release this summer. It has a lot to prove: The company had a disappointing Phase 2 readout back in 2016, which makes this forthcoming data make or break. 

Read more.